Opendata, web and dolomites

Tuberculini SIGNED

A novel in-vitro diagnostic test for drug-resistant tuberculosis and a personalized antibiotic treatment plan.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Tuberculini project word cloud

Explore the words cloud of the Tuberculini project. It provides you a very rough idea of what is the project "Tuberculini" about.

death    p1    proprietary    obtaining    sme    generation    off    lifescience    detect    followed    drug    susceptibility    market    therapy    ngs    diagnose    disease    personalized    dna    university    becton    learning    primers    tests    advice    tuberculosis    inability    resistant    matching    minimum    profiles    spin    world    competitive    ivd    analyze    smei    opportunity    caused    dickinson    feasibility    data    ivds    hours    10k    antimicrobial    solution    patient    rapid    clemedi    battle    uses    diseases    hain    founded    causes    swiss    antibiotic    companies    detection    48    annotate    samples    infections    24    73    competitors    financial    plan    addressable    resistance    zurich    larger    person    vitro    valued    mortalities    2019    machine    contributor    tb    algorithms    company    positively    prescription    business    diagnostic    sequencing    commercial    cepheid    infectious    ag    mdr    diagnosed    240k    significantly    12    advantage    amplify    antibiotics    2050    vision    tuberculini    platform    global    total    vs   

Project "Tuberculini" data sheet

The following table provides information about the project.

Coordinator
CLEMEDI AG 

Organization address
address: WAGISTRASSE 12
city: SCHLIEREN
postcode: CH-8952
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2020-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CLEMEDI AG CH (SCHLIEREN) coordinator 50˙000.00

Map

 Project objective

Company: Clemedi AG is a Swiss SME, founded in 2019 as a spin-off from the University of Zurich, with the aim to develop in vitro diagnostic (IVD) tests for antibiotic resistance and susceptibility in infectious diseases. The vision of Clemedi is to support the global battle against antibiotic resistance by developing IVDs that will allow personalized prescription of antibiotics.

Need to address: Antimicrobial resistant infections will be among the world’s leading causes of death by 2050. Multi-drug-resistant tuberculosis (MDR-TB) is a large contributor to death by antimicrobial resistance, with over 240k global mortalities (of which 10k in Europe) per year. Many of these are caused by the inability to detect resistance and antibiotic susceptibility in the diagnostic process.

Solution: Clemedi is developing a unique platform to rapidly diagnose drug-resistant infectious diseases, including MDR-TB, and rapidly provide a matching therapy plan. The platform uses proprietary primers to amplify specific DNA from patient samples, followed by next-generation sequencing (NGS) analysis. Machine-learning algorithms are then used to annotate the NGS data, and determine susceptibility or resistance based on DNA-profiles to provide a focused advice on antibiotic therapy, within 24-48 hours after obtaining a patient’s sample.

Business opportunity: The minimum total addressable market for Clemedi (i.e. every person that needs to be diagnosed for MDR-TB) is valued at €73.7 M. Competitors are companies that also develop IVDs for rapid detection of MDR-TB, such as Hain Lifescience, Cepheid and Becton-Dickinson. The main competitive advantage of Tuberculini is its ability to analyze susceptibility for a significantly larger number of antibiotics (12 vs. 1-5). Only this can positively impact disease management.

Feasibility study: Financial support from the SMEi P1 will be used to assess the technical and commercial feasibility of Tuberculini, Clemedi’s IVD for MDR-TB.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TUBERCULINI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TUBERCULINI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

HAC (2019)

ADVANCED TREATMENT OF CONTAMINATED SOIL

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More